About the Authors

Elisabet Matas

ematas@bellvitgehospital.cat

Affiliation Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Laura Bau

Affiliation Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

María Martínez-Iniesta

Affiliation Translational Research Laboratory, Institut Català d'Oncologia- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Lucía Romero-Pinel

Affiliation Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

M. Alba Mañé

Affiliations Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, Department of Neurology, Joan XXIII University Hospital, Universitat Rovira I Virgili, Tarragona, Spain

Álvaro Cobo-Calvo

Affiliation Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Sergio Martínez-Yélamos

Affiliation Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Competing Interests

The authors have read the journal's policy and have the following competing interests: E. Matas received honoraria from speaking engagements from Biogen, Teva and Merck Serono; research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. L. Bau received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. M. Martínez-Iniesta reports no disclosures. L. Romero-Pinel received honoraria from speaking engagements from Biogen, Teva and Merck Serono; research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. M.A. Mañé received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. A. Cobo-Calvo received research support, funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer Schering Pharma and Merck Serono. S. Martínez-Yélamos received honoraria from speaking engagements, served on a scientific advisory board, collaborates as a consultant and scientific communications and received funding for travel and congress expenses from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Merck Serono, Novartis and Bayer Schering Pharma. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: EM MMI SMY. Performed the experiments: EM LB MMI LRP MAM ACC. Analyzed the data: EM MMI SMY. Contributed reagents/materials/analysis tools: EM MMI SMY. Wrote the paper: EM LB MMI LRP MAM ACC SMY.